23.11.2016
SHOP APOTHEKE EUROPE N.V. NL0012044747
DGAP-News: SHOP APOTHEKE EUROPE with strong revenue growth in the first 9 months of 2016.
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Quarterly / Interim
Statement
SHOP APOTHEKE EUROPE with strong revenue growth in the first 9 months of
2016.
23.11.2016 / 07:27
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA,
AUSTRALIA OR JAPAN.
SHOP APOTHEKE EUROPE with strong revenue growth in the first 9 months of
2016.
* Revenues grew by 37 percent to EUR 124.7 million (9M 2015: EUR 91.0
million)
* Revenues from International activities more than tripled to EUR 18.4
million (9M 2015: EUR 5.2 million)
* Adjusted Segment EBITDA in German core business grew to EUR 3.0 million
(9M 2015: EUR 0.5 million)
* FARMALINE acquisition and IPO facilitate accelerated international growth
* Strong revenue growth expected for Q4 2016
Venlo/Cologne, 23 November 2016 - SHOP APOTHEKE EUROPE N.V., one of the
leading online pharmacies in Continental Europe with a focus on
over-the-counter medication (OTC) and pharmacy-related beauty and personal
care products (BPC), has again grown strongly over the first 9 months of
this financial year and increased revenues by 37 percent to EUR 125
million year on year. The strong business in the German core market and
particularly the successful development of the international online shops
that SHOP APOTHEKE EUROPE is operating under its brand and the FARMALINE
brand, contributed to these results. By acquiring FARMALINE, an online
pharmacy with a broad footprint in Continental Europe, in mid-September
2016 and successfully completing its initial public offering (IPO) shortly
after the end of the third quarter, SHOP APOTHEKE EUROPE has reached
crucial strategic milestones that will enable it to further accelerate the
expansion of its business across Continental Europe.
"Our main focus over the past weeks and months has been on establishing the
framework to enable our growth plans for the next years. The results for
the first 9 months 2016 highlight both the strengths of our German business
in which we increased both revenues and profitability as well as the
substantial growth potential of the International segment. We will use the
IPO proceeds to accelerate the Continental European rollout based on our
leading position in the European market," says Michael Köhler, CEO of SHOP
APOTHEKE EUROPE.
Increase in active clients and a strong existing customer base drive
revenue growth.
The positive development of consolidated revenue and consolidated gross
profit was mainly driven by the significant growth of the core segments
"Germany" and "International". The revenue in the segment Germany grew by
25 percent to EUR 105.1 million (9M 2015: EUR 84.2 million) based on an
increase in active clients to 1.6 million and a consistently high
percentage of orders from existing clients while revenues in the segment
International more than tripled to EUR 18.4 million (9M 2015: EUR 5.2
million).
The third segment "Germany Services", which combines the online services of
the subsidiary Xsite GmbH, also improved and generated revenues of EUR 3.0
million.
Gross profit over the period reached EUR 25.6 million compared with EUR
19.2 million in the first nine months of 2015 and improved across all
segments in the third quarter of this financial year.
Profitable growth in the German core market.
In the core segment Germany, the focus will be on profitable growth which
will benefit from two mediumterm drivers: the already strong market share
of SHOP APOTHEKE EUROPE in Germany and the comparatively higher online
market penetration, which largely results from existing client orders. This
is reflected in the 9 months adjusted segment EBITDA for Germany which
improved significantly year on year to EUR 3.0 million (9M 2015: EUR 0.5
million).
As a result of the international expansion strategy and the higher customer
acquisition costs in connection with the substantial increase in new
customers in the International segment, adjusted segment EBITDA over the
first nine months in the International segment declined as anticipated to
EUR -3.2 million (9M 2015: EUR -1.2 million).
With EUR 0.7 million as at 30 September 2016, the segment EBITDA in Germany
Services fell slightly short of the EUR 0.9 million generated over the same
period of the previous year due to internal development projects.
FARMALINE integration completed.
For the fourth quarter of 2016, SHOP APOTHEKE EUROPE anticipates a
continuation of the positive revenue trend achieved over the first nine
months of this financial year and particularly significant growth of the
segment International on the back of the FARMALINE acquisition. The
acquisition of the Belgium based online pharmacy, which has already been
fully integrated into SHOP APOTHEKE EUROPE and will significantly
contribute to sales growth in the fourth quarter 2016 and beyond.
SHOP APOTHEKE EUROPE also targets a year-on-year improvement of its
consolidated gross profit margin for the full financial year 2016. The
company intends to use the proceeds from its IPO in mid-October primarily
for financing the continued growth of SHOP APOTHEKE EUROPE, inter alia by
investing in IT infrastructure, increased capacity and additional
automation. This investments have already started with the installation of
a high-bay warehouse system at the central logistics site in Venlo,
Netherlands.
The 9 month interim statement of SHOP APOTHEKE EUROPE is available online.
The publication dates for financial year 2017 will be announced in the
coming weeks in the investor relations section of the corporate website
www.shop-apotheke-europe.com.
ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is one of Continental Europe's leading online
pharmacies with a portfolio that focuses on OTC medication and
pharmacy-related BPC products. The Company operates online pharmacies in
Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In
Germany,
TÜV-certified shop-apotheke.com is the market leader in terms of traffic.
SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original
products to about 1.6 million active customers quickly and at a good price.
In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent
pharmaceutical services. SHOP APOTHEKE EUROPE generated over EUR 125
million in revenues in the financial year 2015. Headquartered in Venlo
(Netherlands), SHOP APOTHEKE EUROPE also has an administration site for its
sales and marketing units in Cologne (Germany). The online pharmacy has
been listed on the regulated market of the Frankfurt Stock Exchange (Prime
Standard) since 13 October 2016.
MEDIA CONTACTS
Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Bettina Fries
Mobile: +49 172 297 62 43
Email: [email protected]
Disclaimer
This announcement does not, and shall not, in any circumstances constitute
a public offering, nor an offer to subscribe any securities in any
jurisdiction. The offering was made only on the basis of the securities
prospectus issued by the Company in connection with the offering. The
shares have already been sold.
This communication is not for publication or distribution, directly or
indirectly, in or into the United States, Canada, Australia or Japan. This
communication does not constitute or form part of an offer of securities
for sale or solicitation of an offer to purchase securities in the United
States, Canada, Australia, Japan or in any other jurisdiction in which such
offer may be restricted. The securities referred to in this communication
have not been, and will not be, registered under the US Securities Act of
1933, as amended (the "Securities Act"), and may not be offered or sold in
the United States, except on the basis of an applicable exemption from the
registration requirements or in a transaction not subject to the
registration requirements of the Securities Act. There will be no public
offering of securities in the United States.
In the United Kingdom, this communication is directed only at persons who:
(i) are qualified investors within the meaning of the Financial Services
and Markets Act 2000 (as amended) and any relevant implementing measures
and/or (ii) are outside the United Kingdom or (iii) have professional
experience in matters relating to investments and fall within the
definition of "investment professionals" contained in article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended) (the "Order") or are persons falling within article 49(2)(a)
to (d) (high net worth companies, unincorporated associations, etc.) of the
Order, or fall within another exemption to the Order (all such persons
referred to in (i) to (iii) above together being referred to as "Relevant
Persons"). Any person who is not a Relevant Person must not act or rely on
this communication or any of its contents. Any investment or investment
activity to which this communication relates is available only to Relevant
Persons and will be engaged in only with Relevant Persons.
This communication contains statements related to future business and
financial performance and future events or developments involving SHOP
APOTHEKE EUROPE that may constitute forward-looking statements.
These statements may be identified by words such as "expect", "intend",
"look forward to", "believe", "will" or other words of similar meaning.
Such statements are based on current expectations and certain assumptions
of SHOP APOTHEKE EUROPE's management, of which many are out of our control.
These are subjects to a number of risks and uncertainties. Should one or
more of this risks or uncertainties materialize, or should underlying
expectations not occur or assumptions prove incorrect, actual results,
performance or achievements of SHOP APOTHEKE EUROPE may (negatively or
positively) vary materially from those described explicitly or implicitly
in the relevant forward-looking statement. SHOP APOTHEKE EUROPE does not
intend or assume any obligation to update or revise these forward-looking
statements in light of developments which differ from those anticipated.
---------------------------------------------------------------------------
23.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747
WKN: A2AR94
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
523443 23.11.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
SHOP APOTHEKE EUROPE N.V. ISIN: NL0012044747 können Sie bei EQS abrufen
E-Commerce , A2AR94 , RDC , XETR:RDC